Dual Antidiabetic Mechanism
Combines Sitagliptin, a DPP-4 inhibitor, with Metformin, a biguanide antidiabetic agent, providing complementary control of blood glucose levels in patients with type 2 diabetes.
Loading...
Loading...
Sitagliptin 100 mg + Metformin 500 mg
A dual-action oral antidiabetic combination designed to improve glycemic control in patients with type 2 diabetes mellitus. SITACARE-M combines sitagliptin and metformin to regulate blood glucose levels through complementary mechanisms that enhance insulin release and reduce glucose production.
A dual-action oral antidiabetic combination designed to improve glycemic control in patients with type 2 diabetes mellitus. SITACARE-M combines sitagliptin and metformin to regulate blood glucose levels through complementary mechanisms that enhance insulin release and reduce glucose production.
Combines Sitagliptin, a DPP-4 inhibitor, with Metformin, a biguanide antidiabetic agent, providing complementary control of blood glucose levels in patients with type 2 diabetes.
Sitagliptin blocks the DPP-4 enzyme, increasing incretin hormone levels which stimulate the pancreas to release insulin when blood glucose levels rise after meals.
Metformin decreases glucose production in the liver and reduces intestinal absorption of glucose, helping lower overall blood sugar levels.
Metformin enhances the body’s sensitivity...
Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.
Metformin Hcl. 500mg +Glimpride 1 mg (Bilayered Tablets)
Metformin Hcl. 500mg + Glimpride 2 mg (Bilayered Tablets)
